2005 Public Consultations on Drug Price Issues

Last spring we received a number of stakeholder submissions in response to our Discussion Paper on Drug Price Increases, released in March. Among others, stakeholders raised a number of complex issues concerning the continued appropriateness and relevance of the current Excessive Price Guidelines.

The Board decided, at its December meeting, that certain issues raised by stakeholders require both further analysis and consultation with them. The April NEWSletter will lay out details regarding the work plan relating to this issue for the coming year.